Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case

详细信息    查看全文

• 作者：Kaoru Kaseda (1)
  Ken-ichi Watanabe (1)
  Keisuke Asakura (1)
  Akio Kazama (2)
  
  1. Department of Thoracic Surgery ; Sagamihara Kyodo Hospital ; 2-8-18 Hashimoto ; Midori-ku ; Sagamihara ; Kanagawa ; 252-5188 ; Japan
  2. Department of Pathology ; Sagamihara Kyodo Hospital ; 2-8-18 Hashimoto ; Midori-ku ; Sagamihara ; Kanagawa ; 252-5188 ; Japan
  
• 关键词：Salvage surgery ; Crizotinib ; Anaplastic lymphoma kinase ; Non ; small cell lung cancer
• 刊名：World Journal of Surgical Oncology
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：13
• 期：1
• 全文大小：804 KB
• 参考文献：1. Soda, M, Choi, YL, Enomoto, M, Takada, S, Yamashita, Y, Ishikawa, S (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: pp. 561-6 45" target="_blank" title="It opens in new window">CrossRef
  2. Rikova, K, Guo, A, Zeng, Q, Possemato, A, Yu, J, Haack, H (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: pp. 1190-203 CrossRef
  3. Shaw, AT, Yeap, BY, Mino-Kenudson, M, Digumarthy, SR, Costa, DB, Heist, RS (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: pp. 4247-53 CrossRef
  4. Camidge, DR, Doebele, RC (2012) Treating ALK-positive lung cancer鈥攅arly successes and future challenges. Nat Rev Clin Oncol 9: pp. 268-77 43" target="_blank" title="It opens in new window">CrossRef
  5. Blackhall, FH, Peters, S, Bubendorf, L, Dafni, U, Kerr, KM, Hager, H (2014) Prevalence and clinical outcomes for patients with ALK-positive resected stage I-III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 32: pp. 2780-7 4.5921" target="_blank" title="It opens in new window">CrossRef
  6. Christensen, JG, Zou, HY, Arango, ME, Li, Q, Lee, JH, McDonnell, SR (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6: pp. 3314-22 CrossRef
  7. Kwak, EL, Bang, YJ, Camidge, DR, Shaw, AT, Solomon, B, Maki, RG (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: pp. 1693-703 448" target="_blank" title="It opens in new window">CrossRef
  8. Camidge, DR, Bang, YJ, Kwak, EL, Iafrate, AJ, Varella-Garcia, M, Fox, SB (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13: pp. 1011-9 470-2045(12)70344-3" target="_blank" title="It opens in new window">CrossRef
  9. Kim, D-W, Ahn, M-J, Shi, Y, De Pas, TM, Yang, P-C, Riely, GJ (2012) Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 30: pp. abstract 7533
  10. Shaw, AT, Kim, DW, Nakagawa, K, Seto, T, Crino, L, Ahn, MJ (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: pp. 2385-94 4886" target="_blank" title="It opens in new window">CrossRef
  11. Solomon, BJ, Mok, T, Kim, DW, Wu, YL, Nakagawa, K, Mekhail, T (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371: pp. 2167-77 408440" target="_blank" title="It opens in new window">CrossRef
  12. Takamochi, K, Suzuki, K, Sugimura, H, Funai, K, Mori, H, Bashar, AH (2007) Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer 58: pp. 149-55 4.016" target="_blank" title="It opens in new window">CrossRef
  13. Hishida, T, Nagai, K, Mitsudomi, T, Yokoi, K, Kondo, H, Horinouchi, H (2010) Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. J Thorac Cardiovasc Surg 140: pp. 69-71 CrossRef
  14. Kappers, I, Klomp, HM, Burgers, JA, Zandwijk, N, Haas, RL, Pel, R (2008) Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. J Clin Oncol 26: pp. 4205-7 CrossRef
  
• 刊物主题：Surgical Oncology;
• 出版者：BioMed Central
• ISSN：1477-7819

文摘

A 45-year-old female was diagnosed as having lung adenocarcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement, stage IV (T2bN3M1b). She was treated with crizotinib as second-line chemotherapy. The clinical stage after crizotinib treatment was ycT2aN0M0, stage IB. We performed a left lower lobectomy and lymph node dissection aimed at local control and pathological confirmation of the remaining tumor. The final pathological stage was ypT2aN2M0, stage IIIA with Ef 1b. To the best of our knowledge, this is the first case report of surgical resection in ALK rearrangement-positive lung adenocarcinoma after crizotinib treatment.